LJPC 501

Drug Profile

LJPC 501

Alternative Names: ANGII; Angiotensin-II - LJPC; Giapreza; LJPC501

Latest Information Update: 19 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator La Jolla Pharmaceutical Company
  • Class Neuropeptides; Oligopeptides; Peptide hormones; Vasoconstrictors
  • Mechanism of Action Angiotensin-type-1-receptor-agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypotension
  • Discontinued Hepatorenal syndrome

Most Recent Events

  • 19 Jul 2018 Phase-II clinical trials in Hypotension (In adolescents, In children) in Belgium, before July 2018 (IV) (EudraCT2017-005153-37)
  • 25 Jun 2018 Preregistration for Hypotension in European Union (IV)
  • 25 Jun 2018 EMA validates MAA for LJPC 501 for Hypotension for review
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top